Thompson A. Peter's Insider Trades & SAST Disclosures
Thompson A. Peter's most recent trade in Edgewise Therapeutics Inc was a trade of 372,578 Common Stock done at an average price of $20.1 . Disclosure was reported to the exchange on April 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Thompson A. Peter.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 20.13 per share. | 03 Apr 2025 | 372,578 | 14,809,075 | - | 20.1 | 7,499,995 | Common Stock |
| Edgewise Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 20.13 per share. | 03 Apr 2025 | 124,193 | 443,792 | - | 20.1 | 2,500,005 | Common Stock |
| Sionna Therapeutics Inc. | Peter A. Thompson | Director | 10 Feb 2025 | 3,154,959 | 3,154,959 | - | - | Common Stock | ||
| Sionna Therapeutics Inc. | Peter A. Thompson | Director | 10 Feb 2025 | 2,560,951 | 0 | - | - | Series B convertible preferred stock | ||
| Sionna Therapeutics Inc. | Peter A. Thompson | Director | 10 Feb 2025 | 2,048,760 | 0 | - | - | Series C convertible preferred stock | ||
| Sionna Therapeutics Inc. | Peter A. Thompson | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 10 Feb 2025 | 550,000 | 3,704,959 | - | 18 | 9,900,000 | Common Stock |
| ARS Pharmaceuticals Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 26 Aug 2024 | 83,695 | 0 | - | 13 | 1,088,035 | Common Stock |
| ARS Pharmaceuticals Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 13.52 per share. | 21 Aug 2024 | 394,400 | 557,977 | - | 13.5 | 5,332,288 | Common Stock |
| ARS Pharmaceuticals Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 21 Aug 2024 | 391,482 | 153,195 | - | 12.9 | 5,065,777 | Common Stock |
| ARS Pharmaceuticals Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 13.03 per share. | 21 Aug 2024 | 69,500 | 83,695 | - | 13.0 | 905,585 | Common Stock |
| ARS Pharmaceuticals Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 14.61 per share. | 21 Aug 2024 | 13,300 | 544,677 | - | 14.6 | 194,313 | Common Stock |
| ARS Pharmaceuticals Inc | Peter A. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Corvus Pharmaceuticals Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 20,594 | 20,594 | - | - | Stock Options (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | 18 May 2024 | 2,416,181 | 0 (0%) | 12% | - | Common Stock | ||
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | 18 May 2024 | 264,315 | 0 (0%) | 1% | - | Common Stock | ||
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 17,500 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 10,000 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 10,000 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Corvus Pharmaceuticals Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 May 2024 | 1,444,085 | 1,444,085 | - | - | Pre-Funded Warrants (right to buy) | |
| Corvus Pharmaceuticals Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 May 2024 | 1,397,684 | 1,397,684 | - | - | Common Warrants (right to buy) | |
| Edgewise Therapeutics Inc | Thompson Peter A. | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 11.00 per share. | 23 Jan 2024 | 454,545 | 14,436,497 | - | 11 | 4,999,995 | Common Stock |
| Alpine Immune Sciences Inc | A. Peter Thompson | Director | 11 Jan 2024 | 145,251 | 0 | - | - | Warrant (Right to Buy) | ||
| Alpine Immune Sciences Inc | A. Peter Thompson | Director | 11 Jan 2024 | 145,251 | 2,416,181 (12%) | 0% | 12.7 | 1,850,498 | Common Stock | |
| Alpine Immune Sciences Inc | A. Peter Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 17,500 | 17,500 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Thompson A. Peter | Director | Sale of securities on an exchange or to another person at price $ 18.32 per share. | 27 Dec 2023 | 1,195,683 | 2,270,930 (12%) | 6% | 18.3 | 21,904,913 | Common Stock |
| Alpine Immune Sciences Inc | Peter Thompson A. | Director | Sale of securities on an exchange or to another person at price $ 19.96 per share. | 27 Dec 2023 | 162,576 | 3,493,485 (18%) | 0% | 20.0 | 3,245,017 | Common Stock |
| Alpine Immune Sciences Inc | Thompson Peter A. | Director | Sale of securities on an exchange or to another person at price $ 18.32 per share. | 27 Dec 2023 | 139,166 | 264,315 (1%) | 0% | 18.3 | 2,549,521 | Common Stock |
| Alpine Immune Sciences Inc | Thompson A. Peter | Director | Sale of securities on an exchange or to another person at price $ 19.82 per share. | 27 Dec 2023 | 26,872 | 3,466,613 (18%) | 0% | 19.8 | 532,603 | Common Stock |
| Alpine Immune Sciences Inc | Thompson A. Peter | Director | Sale of securities on an exchange or to another person at price $ 19.96 per share. | 27 Dec 2023 | 18,922 | 406,609 (2%) | 0% | 20.0 | 377,683 | Common Stock |
| Alpine Immune Sciences Inc | A. Thompson Peter | Director | Sale of securities on an exchange or to another person at price $ 19.82 per share. | 27 Dec 2023 | 3,128 | 403,481 (2%) | 0% | 19.8 | 61,997 | Common Stock |
| Corvus Pharmaceuticals Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Peter A. Thompson | Director | Purchase of securities on an exchange or from another person at price $ 6.20 per share. | 29 Aug 2023 | 500,000 | 8,019,187 | - | 6.2 | 3,100,000 | Common Stock |
| ARS Pharmaceuticals Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Corvus Pharmaceuticals Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to buy) | |
| Corvus Pharmaceuticals Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Decibel Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Corvus Pharmaceuticals Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Janux Therapeutics Inc | Peter A. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to buy) | |
| Janux Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 29 Dec 2021 | 36,700 | 2,258,566 | - | 20.3 | 745,010 | Common Stock |
| Janux Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 29 Dec 2021 | 3,700 | 231,098 | - | 20.3 | 75,110 | Common Stock |
| Janux Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 21 Dec 2021 | 108,300 | 2,295,266 | - | 19 | 2,057,700 | Common Stock |
| Janux Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 21 Dec 2021 | 11,100 | 234,798 | - | 19 | 210,900 | Common Stock |
| Janux Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 19.07 per share. | 16 Dec 2021 | 356,800 | 2,403,566 | - | 19.1 | 6,804,176 | Common Stock |
| Janux Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 19.07 per share. | 16 Dec 2021 | 36,500 | 245,898 | - | 19.1 | 696,055 | Common Stock |
| Corvus Pharmaceuticals Inc | Peter A. Thompson | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 6.09 per share. | 20 Sep 2021 | 1,109,644 | 6,943,654 (22%) | 3% | 6.1 | 6,757,732 | Common Stock, $0.0001 par value |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 9.40 per share. | 17 Sep 2021 | 585,106 | 3,656,061 (19%) | 3% | 9.4 | 5,499,996 | Common Stock |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 9.40 per share. | 17 Sep 2021 | 425,531 | 425,531 (2%) | 2% | 9.4 | 3,999,991 | Common Stock |
| Corvus Pharmaceuticals Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Janux Therapeutics Inc | Peter A. Thompson | Director | 15 Jun 2021 | 1,348,421 | 1,348,421 | - | - | Common Stock | ||
| Janux Therapeutics Inc | Peter A. Thompson | Director | 15 Jun 2021 | 1,052,632 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Janux Therapeutics Inc | Peter A. Thompson | Director | 15 Jun 2021 | 823,742 | 2,172,163 | - | - | Common Stock | ||
| Janux Therapeutics Inc | Peter A. Thompson | Director | 15 Jun 2021 | 643,046 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Janux Therapeutics Inc | Peter A. Thompson | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 15 Jun 2021 | 588,203 | 2,760,366 | - | 17 | 9,999,451 | Common Stock |
| Janux Therapeutics Inc | Peter A. Thompson | Director | 15 Jun 2021 | 164,748 | 164,748 | - | - | Common Stock | ||
| Janux Therapeutics Inc | Peter A. Thompson | Director | 15 Jun 2021 | 128,609 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Janux Therapeutics Inc | Peter A. Thompson | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 15 Jun 2021 | 117,650 | 282,398 | - | 17 | 2,000,050 | Common Stock |
| Janux Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Decibel Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | 17 Feb 2021 | 14,480,162 | 0 | - | - | Series D Preferred Stock | ||
| Decibel Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | 17 Feb 2021 | 2,732,106 | 2,732,106 | - | - | Common Stock | ||
| Decibel Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | 17 Feb 2021 | 1,737,619 | 0 | - | - | Series D Preferred Stock | ||
| Corvus Pharmaceuticals Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 3.50 per share. | 17 Feb 2021 | 1,285,714 | 8,053,298 (26%) | 4% | 3.5 | 4,499,999 | Common Stock, $0.0001 par value |
| Decibel Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | 17 Feb 2021 | 1,158,412 | 0 | - | - | Series D Preferred Stock | ||
| Decibel Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 17 Feb 2021 | 1,111,100 | 3,843,206 | - | 18 | 19,999,800 | Common Stock |
| Decibel Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 17 Feb 2021 | 555,566 | 883,418 | - | 18 | 10,000,188 | Common Stock |
| Decibel Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | 17 Feb 2021 | 327,852 | 327,852 | - | - | Common Stock | ||
| Decibel Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | 17 Feb 2021 | 218,568 | 218,568 | - | - | Common Stock | ||
| Decibel Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 7,650 | 7,650 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 14.25 per share. | 28 Dec 2020 | 600,000 | 3,070,955 (16%) | 3% | 14.3 | 8,550,000 | Common Stock |
| Corvus Pharmaceuticals Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges